GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tianjin Pharmaceutical Da Ren Tang Group Corp 600329.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

41.77

-0.83%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tianjin Pharmaceutical Da Ren Tang Group Corp

Its shares trade on Shanghai under the ticker 600329.SS. It has been listed since 6 June 2001. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.92bn and net income of CN¥2.13bn. At that date it held total assets of CN¥11.69bn and shareholders' equity of CN¥7.10bn.

Tianjin Zhong Xin Pharmaceutical Group Corp. Ltd. engages in the manufacture and sale of traditional Chinese medicine. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2001-06-06. The firm's principal businesses include the research, development and manufacture of Chinese patent medicines, Chinese herbal medicines, chemical raw materials and preparations, biomedicine and nutraceuticals, as well as the distribution of pharmaceuticals. The firm's main products include cardiovascular and respiratory medicines, gastrointestinal drugs and anti-cancer drugs.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
6 Jun 2001
Employees
4,720

Leadership

Pay as last reported

  • Ms. Lei WangChairman of the Board, since 2013CN¥2.6m
  • Mr. Jian MaChief Financial OfficerCN¥190,300
  • Ms. Shengfang NiuChief Accounting OfficerCN¥1.1m
  • Mr. Hong ZhouDeputy General Manager, Director, Chief Engineer, since 2012CN¥1.4m
  • Mr. Yu ZhangChief Manufacturing OfficerCN¥893,800
  • Ms. Yan JiaoSecretary of the BoardCN¥445,800
  • Mr. Min GuoDirector
  • Ms. Weiwen MaoDirector
  • Mr. Mingjie ShangStaff Elected DirectorCN¥299,000
  • Mr. Jianhua XingDirector
  • Mr. Yoke Pheng LiewIndependent DirectorCN¥292,433
  • Mr. Guat Kwang YeoIndependent DirectorCN¥24,458

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
72
Environment
85
Social
43
Governance
89
Direct emissions (scope 1)
4,228.38 t
Energy emissions (scope 2)
24,689.63 t
Women in the workforce
49.77836%
Carbon reduction policy
Yes
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd possesses several strengths that contribute to its success:

Weaknesses

  • Despite its strengths, Tianjin Zhongxin Pharmaceutical Group Corp Ltd also faces certain weaknesses:

Opportunities

  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd can leverage the following opportunities to grow its business:

Threats

  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd should be mindful of the following threats in the industry:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.